We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3037:TWSEUnimicron Technology Corp. Analysis

Data as of 2026-03-13 - not real-time

NT$508.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Unimicron Technology Corp. (3037.TW) is trading at TWD 508, just shy of its 52‑week high of 509 and well above the computed fair value of 189, indicating a steep premium. The stock sits above its 20‑day SMA (424) and 50‑day SMA (335), with a bullish MACD histogram (+0.83) and a relatively high RSI of 67, suggesting continued upward momentum but also approaching overbought territory. Volatility is elevated at 95% (30‑day) and beta hovers around 1.0, reflecting market‑aligned risk, while volume trends are decreasing, hinting at waning buying pressure. Fundamentally, revenue grew 18% year‑over‑year, yet margins remain thin (gross 13.9%, operating 6.8%) and free cash flow is negative, compounded by a high debt‑to‑equity ratio of 56. The PE ratio of 117 dwarfs the industry average of 33, and despite a modest dividend yield of 0.31% with a 34% payout, cash generation concerns cast doubt on sustainability.
Given the bullish technical backdrop but stark overvaluation, limited cash flow cushion, and elevated volatility, the stock appears poised for short‑term price pressure near resistance, while longer‑term upside is constrained by fundamental imbalances and valuation disconnect.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance (509) with bullish MACD
  • High RSI indicating potential short‑term pullback
  • Decreasing volume suggesting waning momentum

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth but thin profit margins
  • Elevated valuation multiples versus peers
  • Negative free cash flow and high leverage

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Price far above DCF fair value (189) and forward PE 25
  • Sustained overvaluation risk with limited cash generation
  • High debt burden and modest dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth18.10%
Profit Margin5.08%
P/E Ratio117.6
ROE7.31%
ROA1.71%
Debt/Equity56.33
P/B Ratio7.7
Op. Cash FlowNT$15.0B
Free Cash FlowNT$-4881800704
Industry P/E33.7

Technical Analysis

TrendBullish
RSI67.1
SupportNT$329.00
ResistanceNT$509.00
MA 20NT$424.15
MA 50NT$335.39
MA 200NT$192.78
MACDBullish
VolumeDecreasing
Fear & Greed Index72.23

Valuation

Fair ValueNT$189.23
Target PriceNT$520.47
Upside/Downside2.45%
GradeOvervalued
TypeGrowth
Dividend Yield0.31%

Risk Assessment

Beta1.01
Volatility95.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.